$Schrodinger(SDGR.US)$having use there platform and I absolutely see the growth potential. eventually the aoftware businees will boost the growth.$Schrodinger(SDGR.US)$is definitely leader in Bioinformatics. holding it until 60$
Schrödinger's forecast downgrade, with higher losses and lower revenue estimates, could make the market wary. The expected revenue drop contrasts with the wider industry's projected 11% annual growth, hinting Schrödinger may trail its peers.
QianmengYu : 不,這意味著放棄。IND 之後,BMY 不認為這種藥物有前途,即使在第一階段也不想投資/投注。不再有里程碑付款(先前的付款不可退還)。